Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL30604704 | 0.98 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL1118353 | 0.86 | CA2 (0.40) | CA2CA1CA9 | |
| SCHEMBL1118616 | 0.84 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL1032931 | 0.84 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL16148467 | 0.82 | CA2 (0.38) | CA2CA1CA9 | |
| SCHEMBL29018668 | 0.82 | CA2 (0.38) | CA2CA1CA9 | |
| SCHEMBL26981905 | 0.82 | CA2 (0.38) | CA2CA1CA9 | |
| SCHEMBL575713 | 0.79 | CA2 (0.44) | CA2CA1CA9 | |
| SCHEMBL20191736 | 0.79 | CA2 (0.38) | CA2CA1CA9 | |
| SCHEMBL576009 | 0.79 | CA2 (0.44) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349822-B | Biological macromolecule modification method based on vinyl sulfonium salt | 深圳湾实验室坪山生物医药研发转化中心 | 2023-10-20 | — | — | CN | claimed |
| EP-1155023-B1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO SPA (IT) | 2005-03-02 | — | — | EP | claimed |
| JP-2003518131-A | — | — | 2003-06-03 | — | — | JP | claimed |
| US-6509324-B1 | Use as contrast agents in magnetic resonance imaging | BRACCO S.P.A. (IT) | 2003-01-21 | — | — | US | claimed |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2003-01-16 | — | — | US | claimed |
| EP-1155023-A1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.p.A. (IT) | 2001-11-21 | — | — | EP | claimed |
| WO-2001046207-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2001-06-28 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-5665772-A | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | SANDOZ LTD. (CH) | 1997-09-09 | — | — | US | disclosed |
| EP-0737195-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-10-16 | — | — | EP | disclosed |
| US-5541183-A | RESPIRATORY SYSTEM DISORDERS, SKIN DISORDERS AND PLATELET ACTIVATING FACTOR ANTAGONIST | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-07-30 | — | — | US | disclosed |
| WO-1996020928-A1 | PIPERIDINE-BASED SIGMA RECEPTOR LIGANDS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 1996-07-11 | — | — | WO | disclosed |
| EP-0663916-A1 | O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS | SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H. (AT) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995018131-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994009010-A1 | O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CA2 3170/4885CA1 2977/4885CA9 2069/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | CA2 2935/4885CA1 1784/4885CA9 1384/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CA2 3170/4885CA1 2977/4885CA9 2069/4885 |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | MPI, SLC39A14, LRPPRC | CA2 921/4885CA1 866/4885CA9 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.